{"name":"California Allergy and Asthma Medical Group, Inc.","slug":"california-allergy-and-asthma-medical-group-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Mometasone furoate 220","genericName":"Mometasone furoate 220","slug":"mometasone-furoate-220","indication":"Other","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Mometasone furoate 440","genericName":"Mometasone furoate 440","slug":"mometasone-furoate-440","indication":"Asthma maintenance therapy","status":"marketed"}]}],"pipeline":[{"name":"Mometasone furoate 220","genericName":"Mometasone furoate 220","slug":"mometasone-furoate-220","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Mometasone furoate 440","genericName":"Mometasone furoate 440","slug":"mometasone-furoate-440","phase":"marketed","mechanism":"Mometasone furoate is a corticosteroid that reduces inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator production.","indications":["Asthma maintenance therapy","Allergic rhinitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOVEhsNlJYR00wUkNiVmRLaUdFWjBHU0t6cnFBeVNhTF9iQWI1ZEJoVGt0b2ZCSlN5TnFCdEUtYXlnSXVNd3lOTmVrZElYczVSTlB6Vll0TTEwbFIzTENIeXQ3UU5FWUVuQV9uTnVlTkxua1hpREhGVUFPdXJuVXpXRVZYbERJcjBjaDhta3hNYS16V05CRHdrZkhmYm9VYkxQeDlQT0VWaHpVUVpadEVLbHYzNHljZU9mVXBZZ1hxYUpHcy0tNV9PdklR?oc=5","date":"2026-03-27","type":"pipeline","source":"Reuters","summary":"Novartis to pay up to $2 billion for US biotech firm Excellergy - Reuters","headline":"Novartis to pay up to $2 billion for US biotech firm Excellergy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxNbU12ZXNlekp4WV9pZW1pdnVrdWExOWVtUWFKY0ZaTFllZVo5aEhrQThOdEt0cTZOUVU1aTVKUjlSZzRxaGlUZHpkM0tmUlpMdW9QMDlUQ0t4cl9uQWJ4TjgtS0loT2ZhRmZjQVhUT0E4cjl2SGpnMTZXWEZaU0FoN2J4ckdzOGFyYUZkOUFLLW9MOUIxLWZBZUhFdUUxUVFPbURWQndLX2VMTTdjOE0ydDZxa1hkV0ZsUHdZNlNyWGxYTnZNY3ZWYU9XTEZ1ZDl6YUs4LVQwWmJKM1lVYzlmb1VCdUF0NlJKN0tVX3U3RkpYLWVVTF9wR0hLQlVESERKb1ZzLV90cVMtYXpxaFY2MDNMV2RFYkF0c3JwN3g5UQ?oc=5","date":"2026-03-02","type":"trial","source":"businesswire.com","summary":"KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) - businesswire.com","headline":"KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOc0hDT3lyZ2ZLcTczUEFNX09qMmxrU2xlWDBkS3A3THp4TkluSkRlbkEwN3BCMUhScVdNUkhSTWdPYUlNUXFUcTIxRFg5ZHUtOTVPaG1ZY0toWnpuWnlsQVJoc0NWT1ZyeWx4YUQ1STB5cXJzamVOMmR4cWFjTk05WXFiUTl0STlvTUU5V3Rxei1KbjgtaVl6YmszWEZlcG1aYjUxRS1KRFVhaWNfR3BOSk92X0dSYkJBNDdr?oc=5","date":"2026-02-10","type":"pipeline","source":"Stock Titan","summary":"Needle-free epinephrine nasal spray may cut costs and boost patient preference - Stock Titan","headline":"Needle-free epinephrine nasal spray may cut costs and boost patient preference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPYnFiMFZic3dFSU9udGVLQlBIMXlkUU1FSm4zUm9IWkJZY25fVVRQVnVOOG9iUFJmTFhZSW5NaVU1cHZqT0x4QnNRNGx6N1NSRVBzZGtqVDJOcDREb0JPQ29wTkF3ZFBXOE5id3NiLUZxNmR1bUNHMkpnR0hkWHBCRFc5dHJnV3NyZGJPMWdTTnJjXzdWN3dpNUVXaHBRNkNrX2RKbA?oc=5","date":"2025-06-02","type":"pipeline","source":"NBC News","summary":"Parents sue over son's asthma death days after inhaler price soared without warning - NBC News","headline":"Parents sue over son's asthma death days after inhaler price soared without warning","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNY3QtVHpzZ0tyRVloZDhMVi1DS0NtRHc0aFRPOE95eUFBaldZbmlZcmFNeU1mbTd0N25kQVVBbXROV3FDNnVVYnYxdEFJVXBDLVU2Z0tIMl9ob21UTks3NGh5LXpIUmdUSDg4RC15Si1sR1REVDFGbkZEM3hiWnI3am1EWGN6VHNDRUJ6WVBPNGJkOTAtcElfV0p5X2VwYTRPNGZ5RHhGclR5M2Ew?oc=5","date":"2025-04-28","type":"pipeline","source":"Truthout","summary":"One of the Largest Health Insurers Is Making It Harder to Get Asthma Medicine - Truthout","headline":"One of the Largest Health Insurers Is Making It Harder to Get Asthma Medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxPRlhHS0lyRjc2ZjRya05wR1J4eVowNk5ZVnA4TlRZWnp6ODg0NzhYb24xWkI1Q2ZyOWJQTS0xOUg0cGZXZi1BbmhRMWR0N2tBNWd3dDdOSHdhZWRHMzIyZklMZ29BN3FPcnVnMnN0RHptRW5Ybl9ZSG5yaDRqaWdWU3E0S0dmNTM0WnZBQUhRRVRkXzZXdmRaeDEzQ1B2OWc4X3lZSVV6Z1kwTFp2MzkzV2tWUzdyMElLTzlMMk1pZkJ4SHlFdTRhV2NwRnZXN2tKSnAzU25zNzJmMmZNal9mR1JsdDN4T01nLVdSQzdYM1lFcnVGWld4TWt5LVJ1NVVZNkVHNWlKZlRsNjRnVVZUa3BqSDRNbXJMU0VvdHYxeVd5MjdUM04xQUln?oc=5","date":"2025-02-27","type":"pipeline","source":"prnewswire.com","summary":"Nasus Pharma To Present Positive Clinical Results From Recent studies of FMXIN002 (NS002) Intranasal Epinephrine at the 2025 AAAAI Annual Meeting - prnewswire.com","headline":"Nasus Pharma To Present Positive Clinical Results From Recent studies of FMXIN002 (NS002) Intranasal Epinephrine at the ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE5DeWhFUUh3Sk1YZnN4aGpwdVg1enRtM3MzU1VFVlBMMkZBd1hjWHpMbmRlTk5ldXRyZUVvVTNGQnRzVmg0TVprZHotRGlqR2VCZGVibEJTOThRUXdrR1dFaEsza1VKWXd1UGVpXzl2Vno4RkNh?oc=5","date":"2025-02-20","type":"deal","source":"Private Equity Stakeholder Project PESP","summary":"Private Equity Healthcare Deals: 2024 in Review - Private Equity Stakeholder Project PESP","headline":"Private Equity Healthcare Deals: 2024 in Review","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNQXR1SDhMSWgteTlCdExYWWgyenFSaS1FTGowM3RMRzE1UU9EY0J4enpwOGREbU01dXFXM0ZaOVB5LThuOUlPdVNaOFdvSG1YT1hEN1puZjR3b3BiWUVHa1BpeVB4bEcwbUt3bUU1enJMZVgxak5ONDZLZkI5V1dGVW93aDhxMWlQMTVyalZfMFdJM3NMMTQ5eHpmbDdFNzRTLVB2QVJTTTJqWk9SNWgzZmxzbWVGaUtwang1OWxSbkxoYm51MzZHR2JfRQ?oc=5","date":"2024-09-17","type":"pipeline","source":"Dove Medical Press","summary":"JAA - Dove Medical Press","headline":"JAA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQMmRGMzBjdkVOU1dPbEFWcjFYZWlVMDM1bnRyektObkRkQXJHWVFDdGdkQmZ5alE3RzFEaWdFV2Z3dmZPVlhOSTBIQ2lLc2pBRmxqMG9fT2szZnlmV3hFWGFRVk5VR2NBRm5GR21kRjI5eWdHM0E5bTR4bXZWd1hYWUpvYm1QQXZ6SnhUbGNsMVFFeF84bUp3NkNiZkl0YnF6TU9hTnBzTVk2SXNKMlRhNWtKSVN3UXZlUmkxb3hOVmlyZnVRXzBSSWJMdHJTTmg5NjZ5Nnh1d2JKUkJTdkd1bVZQaVEteUE?oc=5","date":"2024-02-16","type":"regulatory","source":"Novartis","summary":"FDA approves Xolair® (omalizumab) as first and only medicine for children and adults with one or more food allergies - Novartis","headline":"FDA approves Xolair® (omalizumab) as first and only medicine for children and adults with one or more food allergies","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBfdXhIMVNtNS1YbWVLWEFsaVVSU0VTRkhTclJqMHFkNWFrOWZJaFh5NnpRMnlpelhLdkdZamtQMVQwcUkyYWRuelJLV1N3Y2NveDc2VENacjdlR19qb1FwOE9ndDQzNTY4NGZ5ZzREUFg5Vm1a?oc=5","date":"2022-04-19","type":"pipeline","source":"GoodRx","summary":"Over-the-Counter Inhalers: The 3 Best Options - GoodRx","headline":"Over-the-Counter Inhalers: The 3 Best Options","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxOQW5MMldYb3FwX0NwWWFjcjgtVFRDR3h2OC1DUndSVFBnUzgtN2FQVzRDbTkzb1BwdU9sRE5lcHI0Mmw0YjZ2OHduUk9ZNFRYUkJEWS03MHVsOWJCMVhLNG5mZVFickRFbmluTnVKQVFlV3BCMlhGUUUxdUFZV2VDV2UzWFNYN3Zpd3VRNzJQWm9fellyVWpkeE5VMG1vLWlxbFgzdTN3clNLN2I3VnhvM04wY2ZuNWtFbnNWUVJOWXNJWG5pbU5vZXlpWGQ3SFZuX2ZneEJCcWFGeGRUT0o5Z3BSMl95elRsdU42NXd4dkFiMDk4dnc?oc=5","date":"2018-07-03","type":"pipeline","source":"24-7 Press Release Newswire","summary":"Doctors of Excellence Recognizes Dr. Warner W. Carr is a Highly Regarded Experienced Allergist and Immunologist - 24-7 Press Release Newswire","headline":"Doctors of Excellence Recognizes Dr. Warner W. Carr is a Highly Regarded Experienced Allergist and Immunologist - 24-7 P","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxQOEx5OVlpRXdWdmZITkN6STBOYXJLb3VlVDRjNG9HT3g5cEI0Q05pOVQ3UUZ4OWU0UV9DYWxfOWFUQU14WXpaR1RXNEhtMXdvOFBLcTRDTmNMR0x1X3ktY0xSQUFoc1VlQ1JmNjFkMlBBTkpPeGtCZ3pIUURiRWs3MTh6Q1d4ZXc5YjdmSWhGUEoxcTVNclU4WGdnOXFKZWhBeVlndVEzSks1QkJxWWdHekdxRHFzdU8xWDVmdlNIY0s3RXFfMzZjdjhkbW1RRlVoSmFHcUZ1MUh3aV9IM3JpNVI1c1NyM05hZnNzbzN1elZ3M0VscnhjZWlsOHBZSUt5aDg2UVRjTnRLSFNVbWRMcDNKZjlfMlE0?oc=5","date":"2018-02-12","type":"pipeline","source":"Teva Pharmaceuticals","summary":"Teva Announces U.S. Launch of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation Aerosol - Teva Pharmaceuticals","headline":"Teva Announces U.S. Launch of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation Aerosol","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}